Please cite this article in press as: Liang, Z., et al., Recent progress and new developments in post-combustion carbon-capture technology with amine based solvents. Int. J. Greenhouse Gas Control (2015), http://dx.Keywords: Recent development of PCC process Design and modeling Solvent development Post Build Operations Solvent chemistry Solvent management Mass transfer with reaction a b s t r a c tCurrently, post-combustion carbon capture (PCC) is the only industrial CO 2 capture technology that is already demonstrated at full commercial scale in the TMC Mongstad in Norway (300,000 tonnes per year CO 2 captured) and BD3 SaskPower in Canada (1 million tonnes per year CO 2 captured). This paper presents a comprehensive review of the most recent information available on all aspects of the PCC processes. It provides designers and operators of amine solvent-based CO 2 capture plants with an in-depth understanding of the most up-to-date fundamental chemistry and physics of the CO 2 absorption technologies using amine-based reactive solvents. Topics covered include chemical analysis, reaction kinetics, CO 2 solubility, and innovative configurations of absorption and stripping columns as well as information on technology applications. The paper also covers in detail the post build operational issues of corrosion prevention and control, solvent management, solvent stability, solvent recycling and reclaiming, intelligent monitoring and plant control including process automation. In addition, the review discusses the most up-to-date insights related to the theoretical basis of plant operation in terms of thermodynamics, transport phenomena, chemical reaction kinetics/engineering, interfacial phenomena, and materials. The insights will assist engineers, scientists, and decision makers working in academia, industry and government, to gain a better appreciation of the post combustion carbon capture technology.

SummaryTrypanosoma brucei, a flagellated protozoan parasite causing human sleeping sickness, relies on a subpellicular microtubule array for maintenance of cell morphology. The flagellum is attached to the cell body through a poorly understood flagellum attachment zone (FAZ), and regulates cell morphogenesis using an unknown mechanism. Here we identified a new FAZ component, CC2D, which contains coiled-coil motifs followed by a C-terminal C2 domain. T. brucei CC2D is present on the FAZ filament, FAZ-juxtaposed ER membrane and the basal bodies. Depletion of CC2D inhibits the assembly of a new FAZ filament, forming a FAZ stub with a relatively fixed size at the base of a detached, but otherwise normal, flagellum. Inhibition of new FAZ formation perturbs subpellicular microtubule organization and generates short daughter cells. The cell length shows a strong linear correlation with FAZ length, in both control cells and in cells with inhibited FAZ assembly. Together, our data support a direct function of FAZ assembly in determining new daughter cell length by regulating subpellicular microtubule synthesis.

ObjectivesTo explore assessment of supra‐annular structure for self‐expanding transcatheter heart valve (THV) size selection in patients with bicuspid aortic stenosis (AS).BackgroundAnnulus‐based device selection from CT measurement is the standard sizing strategy for tricuspid aortic valve before transcatheter aortic valve replacement (TAVR). Because of supra‐annular deformity, device selection for bicuspid AS has not been systemically studied.MethodsTwelve patients with bicuspid AS who underwent TAVR with self‐expanding THVs were included in this study. To assess supra‐annular structure, sequential balloon aortic valvuloplasty was performed in every 2 mm increments until waist sign occurred with less than mild regurgitation. Procedural results and 30 day follow‐up outcomes were analyzed.ResultsSeven patients (58.3%) with 18 mm; three patients (25%) with sequential 18 mm, 20 mm; and only two patients (16.7%) with sequential 18 mm, 20 mm, and 22 mm balloon sizing were performed, respectively. According to the results of supra‐annular assessment, a smaller device size (91.7%) was selected in all but one patient compared with annulus based sizing strategy, and the outcomes were satisfactory with 100% procedural success. No mortality and 1 minor stroke were observed at 30 d follow‐up. The percentage of NYHA III/IV decreased from 83.3% (9/12) to 16.7% (2/12). No new permanent pacemaker implantation and no moderate or severe paravalvular leakage were found.ConclusionsA supra‐annular structure based sizing strategy is feasible for TAVR in patients with bicuspid AS.

Abstract:Objective: The purpose of this study is to evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with a severe stenotic bicuspid aortic valve (BAV) in a Chinese population. While several groups have reported the feasibility, efficacy, and safety of TAVI for patients with a BAV, worldwide experience of the technique is still limited, especially in China. Methods: From March 2013 to November 2014, high surgical risk or inoperable patients with symptomatic severe aortic stenosis (AS) who had undergone TAVI at our institution were selected for inclusion in our study. Results were compared between a BAV group and a tricuspid aortic valve (TAV) group. Results: Forty patients were included in this study, 15 (37.5%) of whom were identified as having a BAV. In the BAV group, the aortic valve area was smaller ((0.47±0.13) vs. (0.59±0.14) cm 2 ), the ascending aortic diameter was larger ((40.4±4.4) vs. (36.4±4.3) mm), and the concomitant aortic regurgitation was lower. No significant differences were found between the groups in the other baseline characteristics. No differences were observed either in the choice of access or valve size. The procedural success achieved in this study was 100%. There were no differences between groups in device success (86.7% vs. 88.0%), 30-d mortality (6.7% vs. 8.0%), or 30-d combined end point (13.3% vs. 12.0%). The incidences of new pacemaker implantation, paravalvular regurgitation and other complications, recovery of left ventricle ejection fraction and heart function were similar in both groups. Conclusions: Patients with a severely stenotic BAV can be treated with TAVI, and their condition after treatment should be similar to that of people with a TAV.

No abstract